Catalyst
Slingshot members are tracking this event:
Regeneron Pharmaceuticals (REGN) trial on DUPIXENT (dupilumab) in food allergy set to begin in second half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| REGN | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Oct 16, 2017
Occurred Source:
https://www.genengnews.com/gen-news-highlights/regeneron-sanofi-cite-progress-in-pursuing-eosinophilic-esophagitis-indication-for-dupixent/81255057
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Dupixent, Dupilumab, Food Allergy
